What Does It Mean to Have Low Grade Cancer?

Low-grade cancer means that, under a microscope, the tumor cells still look relatively similar to normal cells and tend to grow and spread more slowly than higher-grade tumors. A pathologist assigns the grade after examining a tissue sample, and it directly shapes which treatments you receive and how urgently they are needed. But “low grade” does not mean “no big deal,” and the practical implications vary dramatically depending on which organ is affected, your age, and increasingly, your tumor’s molecular profile.

What Determines Cancer Grade

When a pathologist examines a biopsy under a microscope, they compare the tumor cells to the normal cells of that organ. The more the cancer cells resemble healthy tissue in their structure and organization, the lower the grade. Cells that look wildly abnormal, with distorted shapes, disorganized growth patterns, and signs of rapid division, earn a higher grade. Different cancers use different grading scales: prostate cancer has the Gleason system (now often reported as Grade Groups 1 through 5), breast cancer commonly uses the Nottingham grading system, and brain tumors follow the World Health Organization’s grade 1 through 4 scale. Despite these different naming conventions, the underlying logic is the same: how abnormal do the cells look, and how fast do they appear to be growing?

One practical wrinkle with grading is that pathologists don’t always agree. A study examining interobserver variability in Gleason grading for prostate cancer found enough disagreement among pathologists that the authors recommended enhanced training, information sharing, and the use of artificial intelligence tools to improve consistency.¹ This matters because the line between “low grade” and “intermediate grade” can determine whether you’re offered active surveillance or immediate surgery. If your biopsy lands near a grading boundary, getting a second pathology opinion is reasonable.

Revisions to grading systems can also shift where that boundary sits. When the International Society of Urological Pathology updated its Gleason scoring consensus in 2005, the expectation was that the changes would improve how well a biopsy predicted the final surgical grade. In practice, the revision did not lower the rate of grade upgrades found after surgical removal compared to the initial biopsy.² In other words, a biopsy showing low-grade disease sometimes turns out to harbor higher-grade cells that the needle simply missed. This is one reason why surveillance protocols include repeat biopsies over time.

Active Surveillance for Low-Grade Prostate Cancer

Prostate cancer is the most common setting where a low-grade diagnosis leads to a deliberate decision not to treat right away. For men diagnosed with Gleason 6 (Grade Group 1) prostate cancer, active surveillance has become a mainstream management strategy. The idea is straightforward: because many of these tumors will never cause symptoms or shorten your life, you skip the side effects of surgery or radiation and instead monitor the cancer closely, stepping in only if things change.

In a single-surgeon study of 166 men with Gleason 6 disease, about 70% were enrolled in active surveillance. Of those on surveillance, roughly a third eventually moved to definitive treatment over a median follow-up of about two years, and the large majority of those transitions were triggered by signs of disease progression rather than by patient anxiety or preference.³ That means most men stayed safely on surveillance during the study window, and when treatment was needed, it was prompted by an actual change in the cancer.

Monitoring typically involves regular PSA blood tests every three to six months, an annual physical exam, and repeat prostate biopsies every two to five years. Imaging and newer biomarker tests may also be used.⁴ The schedule can feel onerous, and sitting with the knowledge that you have cancer but aren’t treating it requires a kind of patience that doesn’t come easily to everyone. But the data supporting this approach is strong: an analysis of outcomes found that radical prostatectomy provides minimal mortality benefit for men with low-grade prostate cancer specifically, while showing clearer benefit for intermediate-grade disease.⁵ In plain terms, surgery doesn’t meaningfully extend the lives of most men with the lowest-grade prostate cancers.

The Overdiagnosis Problem

The rise of PSA screening for prostate cancer brought an uncomfortable trade-off. Screening catches many cancers earlier, but it also identifies tumors that would never have caused harm if left undiscovered. This phenomenon, called overdiagnosis, is a direct consequence of finding low-grade, slow-growing cancers that would have remained silent for a person’s entire life. Overtreatment follows from overdiagnosis: when those indolent tumors are treated with surgery or radiation, patients face side effects like urinary incontinence and erectile dysfunction without gaining a survival benefit.⁶

This is not a hypothetical concern. Prostate cancer screening programs have driven large increases in the detection of localized, lower-stage tumors, while trends in some populations have shown significant decreases in the incidence of the lowest-grade tumors and increases in higher-grade ones as detection patterns shift.⁷ These trends reflect changing diagnostic practices and screening behavior, not necessarily a biological shift in the disease itself. The challenge for patients and physicians is separating the cancers that need treatment from those that don’t, and low grade is one of the strongest signals that a cancer may fall into the “doesn’t need treatment now” category.

A question people sometimes ask is whether lifestyle changes can slow the progression of a low-grade cancer that’s being watched. A study comparing lifestyle factors in two active surveillance cohorts found that men who remained at low risk did tend to have somewhat higher lifestyle scores and physical activity levels than those who progressed, but on closer statistical analysis, the only consistent predictor of progression was age at diagnosis, not lifestyle.⁸ Healthy habits are worthwhile for many reasons, but there’s currently no strong evidence that diet or exercise can keep a low-grade prostate cancer from upgrading.

Low-Grade Brain Tumors in Adults and Children

Low-grade brain tumors illustrate a different side of the “low grade” story. Unlike prostate cancer, where many low-grade tumors will never affect your health, even a slow-growing brain tumor can cause serious problems simply by pressing on critical brain structures. A grade 2 brain tumor in an area that controls speech or movement can be more disabling than a grade 4 tumor in a surgically accessible location. Grade matters, but location matters just as much.

Among adults, grade 2 gliomas carrying a specific genetic change called an IDH mutation are slow-growing and generally carry a better prognosis than their grade 3 or 4 counterparts, which progress more rapidly. Still, these tumors can undergo what’s called malignant transformation, where a formerly low-grade tumor evolves into a higher-grade one over time. A study of diffuse low-grade gliomas found that about 65% of patients experienced malignant transformation to grade 3 or grade 4, and those who transformed had significantly shorter survival than those whose tumors stayed at grade 2.⁹ Factors associated with a lower risk of transformation included certain genetic features (like a chromosomal change called 1p/19q codeletion), a greater extent of surgical removal, and a lower rate of cell division in the original tumor.

In children, the picture is considerably more hopeful. Pediatric low-grade gliomas are the most common childhood brain tumors, and advances in molecular profiling have revealed that many are driven by specific, targetable genetic alterations in a signaling pathway that controls cell growth. This has opened the door to drugs that specifically block the mutated proteins fueling the tumor.¹⁰ In a clinical trial, children with low-grade gliomas carrying a particular BRAF mutation who received targeted therapy had a response rate of 47%, compared to 11% with traditional chemotherapy. Median progression-free survival was roughly 20 months with the targeted drugs versus about 7 months with chemotherapy.¹¹ These results represent a meaningful shift in how childhood brain tumors are treated, moving away from conventional chemotherapy toward precision approaches tailored to the tumor’s genetic fingerprint.

Low-Grade Blood Cancers and Watch-and-Wait

Follicular lymphoma, the most common slow-growing form of non-Hodgkin lymphoma, presents yet another version of what “low grade” means in practice. Many patients with this cancer are diagnosed when they have no symptoms and a low overall burden of disease in their body. For these patients, the standard approach has long been “watch and wait,” which is essentially the blood cancer equivalent of active surveillance: no treatment until the disease causes problems or shows clear signs of progression.

The rationale is supported by long-term data. A Danish study of 286 patients with advanced-stage follicular lymphoma managed with watch and wait reported a ten-year overall survival of 65%. The risk of dying specifically from the lymphoma within ten years was 13%, and the risk that the cancer would transform into a more aggressive type was about 22% over ten years. The authors concluded that abandoning watch and wait would lead to overtreatment of selected patients.¹² These numbers are worth sitting with: most patients did not die of their lymphoma within a decade, and many never needed treatment at all during that period.

Researchers are also working to predict which patients on watch and wait will need treatment sooner. A study using metabolic imaging found that patients with a lower baseline tumor volume had an 87% probability of remaining treatment-free at two years, compared to about 53% for those with a higher volume.¹³ Tools like this could eventually help tailor the monitoring schedule so that people at very low risk of needing treatment aren’t subjected to unnecessary worry and clinic visits.

When a Cancer Loses Its “Cancer” Label

One of the most striking developments in low-grade oncology has been the outright reclassification of certain tumors. In thyroid cancer, a particular subtype called encapsulated follicular variant of papillary thyroid carcinoma had long been labeled and treated as cancer. But outcome data showed that when the tumor was noninvasive, it almost never spread or recurred after simple surgical removal. In 2016, an international panel of experts formally renamed it “noninvasive follicular thyroid neoplasm with papillary-like nuclear features,” or NIFTP, deliberately dropping the word “carcinoma” from its name.¹⁴

The reclassification was included in the 2017 WHO Classification of Tumours of Endocrine Organs, which describes NIFTP not as a benign tumor but as a neoplasm with “very low malignant potential.” The explicit goal was to prevent overdiagnosis and overtreatment: patients who would previously have been told they had thyroid cancer, with all the fear and aggressive treatment that accompanies that word, could now be managed more conservatively.¹⁵ The NIFTP story is a useful reminder that cancer categories are not fixed truths carved into biology. They are human-made classifications that get revised as evidence accumulates, and sometimes what was called cancer yesterday isn’t called cancer today.

Genomic Testing Beyond the Microscope

Looking at cells under a microscope tells you a lot, but it doesn’t tell you everything. Two tumors that look identical under the lens can behave very differently based on which genes are mutated, amplified, or switched on and off. This is where genomic testing is changing the game for low-grade cancers.

In breast cancer, genomic assays that evaluate the activity of panels of genes can sort tumors into risk categories that are more precise than grade alone. For women with early-stage, hormone-receptor-positive breast cancers that are small and low to intermediate grade, these genomic tests help determine who actually benefits from chemotherapy and who can safely skip it. Research into this population supports using genomic risk scores to guide treatment decisions, with findings suggesting limited benefit from chemotherapy in the lowest-risk subgroups.¹⁶ For a patient, this can mean the difference between months of chemotherapy with its associated side effects and a simpler course of hormonal therapy alone.

Researchers are pursuing similar approaches in cancers where grading has historically been less precise. In pancreatic cancer, one of the most lethal malignancies, a machine learning tool using gene-expression data has shown promise in identifying a subset of tumors that are genuinely lower-grade and may respond better to aggressive surgical approaches.¹⁷ In low-grade serous ovarian cancer, genomic profiling has revealed very low mutation rates and uniformly stable microsatellite status, helping to explain why these tumors behave so differently from their high-grade counterparts and why they tend to respond poorly to standard chemotherapy.¹⁸ As these tools mature, the hope is that “low grade” will increasingly be subdivided into categories precise enough to match each patient with exactly the right level of intervention.

The Emotional Reality of a Low-Grade Diagnosis

Hearing the word “cancer” creates fear, and being told that your particular cancer doesn’t need immediate treatment can be paradoxically distressing. People on active surveillance sometimes struggle with the feeling that they’re doing nothing about a disease that could kill them, even when the evidence supports the strategy. How common is this anxiety, and does it get worse or better over time?

A large prospective study of men on active surveillance for prostate cancer found that about 29% reported cancer-specific anxiety after their first year of monitoring. Over time, though, the anxiety diminished substantially, dropping by roughly half after about seven and a half years on surveillance.¹⁹ The passage of time, along with repeated normal results on monitoring tests, appears to reassure most men that their cancer is genuinely behaving itself.

Another study looking at anxiety and distress in men on active surveillance found small decreases over time in multiple measures of cancer-related anxiety, including fear of progression and self-estimated risk. The changes were statistically detectable but clinically small, which the authors interpreted as meaning that anxiety levels were generally favorable from the start and remained so.²⁰ This is an important finding because one of the arguments against active surveillance has been that it creates an unbearable psychological burden. The data don’t bear that out for most men, though it clearly affects some individuals more than others.

It’s also worth noting that treatment itself doesn’t necessarily make the anxiety go away. Research comparing depression and anxiety rates between men managed with active surveillance, surgery, and radiation found no significant differences across the three groups. About a third of men in each group reported some level of anxiety regardless of which path they chose.²¹ Cancer-related worry, in other words, seems to be more about having a cancer diagnosis at all than about which management strategy you’re on. Choosing surgery to eliminate the anxiety of watching and waiting may not actually eliminate the anxiety.

Experimental Approaches for Resistant Low-Grade Tumors

Not all low-grade cancers stay well-behaved, and some resist the therapies that work for others. In pediatric brain tumors, for instance, even when targeted drugs produce initial responses, tumors can eventually develop resistance. Researchers are exploring combination strategies to address this problem. Early laboratory work on pediatric brain tumor cells carrying both a BRAF mutation and a deletion in a gene called MTAP found that combining two classes of drugs produced an additive or synergistic effect on cell viability beyond what either drug achieved alone.²² This is still preclinical work, meaning it hasn’t been tested in patients yet, but it illustrates how the treatment landscape for even “favorable” low-grade cancers continues to evolve as researchers hunt for ways to overcome resistance and improve outcomes for patients whose tumors don’t follow the expected script.